The company plans to publish the poster, the abstract, and an audio recording tomorrow in a joint press release.
Potent immune response data, supports the previously reported clinical outcome of 0% metastatic breast cancer recurrences over five years of follow-up.
A statistically significant peak immunity was reached after six months of GP2 treatment as measured in both a GP2 specific CD8 T cell dimer binding assay and a delayed-type-hypersensitivity (DTH) skin test.
HER2 3+ population immune response was similar to the HER2 1-2+ population immune response, suggesting the potential to treat the HER2 1-2+ population with GP2 immunotherapy in combination with trastuzumab (Herceptin) based products and other clinically active agents.
GP2 is immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
Price Action: GLSI shares are trading 15.8% higher at $58.5 in premarket trading on the last check Friday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.